Kazia Therapeutics Achieves 100% Clinical Benefit Rate in Initial Patients for Advanced Triple-Negative Breast Cancer

05:44 PM EDT, 08/27/2026 (MT Newswires) -- Kazia Therapeutics (KZIA) said late Thursday new data for its lead asset, paxalisib, achieved a 100% clinical benefit rate in 6 evaluable patients with stage IV triple-negative breast cancer. Some 5 of the 6 patients achieved an objective response, a measurable 30% or more reduction in tumor burden after treatment, including 1 complete response and 4 partial responses, resulting in an objective response rate of 83%, while the remaining patient achieved stable disease, the company said. The results were achieved with oral dosing and a favorable safety and tolerability profile, the company added. The company said it expects enrollment in the ongoing phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in advanced metastatic TNBC to be completed by July 2027, with interim clinical updates throughout 2026 and 2027.